Biotech Holdings (fka BIOHF)

[Renee]

BIOHF revoked:

http://www.sec.gov/litigation/admin/2012/34-66850.pdf

[Renee]

BIOHF SEC Suspension:

http://www.sec.gov/litigation/suspensions/2012/34-66418.pdf

SEC Admin Proceeding:

http://www.sec.gov/litigation/admin/2012/34-66419.pdf

[jackfree]

British Columbia Securities Commission - Cease Trade Order
Dec 13, 2010

OTC Disclosure & News Service

Vancouver, BC, Canada -
2010 BCSECCOM 674


Cease Trade Order

Biotech Holdings Ltd.

Section 164 of the Securities Act, R.S.B.C. 1996, c. 418

¶ 1 Biotech Holdings Ltd. is an OTC reporting issuer under BC Instrument 51-509 Issuers Quoted in the U.S. Over-the-Counter Markets(BCI 51-509).

¶ 2 Biotech Holdings has not filed:


1. comparative annual financial statements for its financial years ended March 31, 2009 and March 31, 2010, as required under Part 4 of National Instrument 51-102 Continuous Disclosure Obligations(NI 51-102) and section 5(b) of BCI 51-509,
2. interim financial statements for the interim periods ended June 30, 2009, September 30, 2009, December 30, 2009, June 30, 2010 and September 30, 2010 as required under Part 4 of NI 51-102 and section 5(b) of BCI 51-509,
3. a Form 51-102F1 Management's Discussion and Analysisfor the periods ended March 31, 2009, June 30, 2009, September 30, 2009, December 31, 2009, March 31, 2010, June 30, 2010 and September 30, 2010 as required under Part 5 of NI 51-102 and section 5(b) of BCI 51-509, and
4. a Form 51-102F2 Annual Information Formfor the years ended March 31, 2009 and March 31, 2010 as required under section 5(c) of BCI 51-509

(the required records).


¶ 3 Under section 164(1) of the Act, the Executive Director orders that all trading in the securities of Biotech Holdings cease until:

1. it files the required records, completed in accordance with the Act and rules, and
2. the Executive Director makes an order under section 164 of the Act revoking this order.


¶ 4 December 13, 2010
Allan Lim, CA
Manager
Corporate Finance

[want to be]

past history
Dec 06 Q was reported on Feb 17 if they follow the same with Mar 07 Q it should be out May 17 hope for the best

[jackfree]

It is nice to see they are turning things around for the longs. I think next Monday they are going to report a sales update and other financial info. I hope we can move to .25 and stay above.

[surf1944]

Another higher move/breakout & new 52 wk high for BIOHF today....should have bought more

[want to be]

BIOHF has broken to the up side with volume Apr 5 2007.
News of sales increase from last Q, will be out by end of month.as per IR Austin.

[surf1944]

BIOHF trying to breakout from trading range, I wouldn't buy into it and at best it looks like it's going sideways.

[albert]

biohf can make 100 contracts with cosco, but nothing helps....
after 11 years of leis company does not have credebility.... SEL SEL verkopen niks waard

[DRCAL]

You are right on BIOHF. However, there are 2 other drug companies with not as good daibetes drugs but more money and marketing power.
If you want a very low priced stock with great potential in treating cancer but with a big legal battle, try HTTD. Hard to Treat Diseases apparently has a treatment that holds off terminal cancer (stage 3 and 4)in patients for up to 15 years. It supresses cancer similiar to drugs that contain the bad effects of hypertension, i.e., the person is able to live with the disease.
I have learned the hard way that whenever there is the potential for something great, there are big lawsuits. Greed is the big factor.

[midastouch017]

BIOTECH HOLDINGS COMPLETES FIRST SUCANON PRODUCTION ORDER



Vancouver, B.C., June 7, 2004 - Robert Rieveley, President of Biotech Holdings (the “Company”, TSX-V: BIO.V; OTC BB: BIOHF) announced today that the Company has completed the first production order of its Sucanon diabetes drug.



“I am pleased to report that our first production order is now completed. We have manufactured Sucanon for 1.2 million tablets or 20,000 one-month treatment packages. We project shipping this production to Mexico this week,” Mr. Rieveley said.



“The value of this shipment is in the range of $240,000 US,” Mr. Rieveley said.



“Monthly shipments of this volume, providing monthly treatment for 20,000 diabetics, would move us easily into profitability. With 10 million reporting Type II diabetics in Mexico and 10 million unreporting, we believe that Mexico offers tremendous potential for ongoing use of Sucanon as an effective and very safe treatment of Type II Diabetes symptoms. Our plant capacity of up to 400,000 one-month treatment packages can be readily expanded as needed,” Mr. Rieveley added.



Biotech Holdings’ Sucanon is an insulin-sensitizing drug for treatment of symptoms of Type II Diabetes and a related condition, Impaired Glucose Tolerance. The drug, in tablet form, improves patients’ ability to utilize insulin, the hormone that controls blood sugar levels.



Biotech Holdings has received regulatory approval for sale of Sucanon in Mexico and Peru as a treatment of Type II Diabetes symptoms. Biotech Holdings has also signed distribution agreements for the drug for Chile, Venezuela, Columbia and Argentina and plans to make regulatory applications for Sucanon in these jurisdictions as well as in Brazil.



Following up on its regulatory approval in Mexico and Peru, the Company expects to make applications shortly in several other jurisdictions in Latin America, including Argentina, Chile, Venezuela



If you would you would like to be added to Biotech Holdings’ email list for future news updates or summary clinical materials, please click here: http://www.biotechltd.com/info.asp



Biotech Holdings Ltd.’s head office is in Richmond, British Columbia. Biotech Holdings’ shares trade on the Over the Counter Bulletin Board in the United States (BIOHF.OB) and on the TSX Venture Exchange in Canada (BIO.V). For inquiries, contact Austin Rand at Biotech Holdings Ltd., 1 888 216 1111 (toll-free), 8:00 a.m. to 4 p.m. Pacific time, or by e-mail at [e-mail]. For background information and current stock quotations, please visit Biotech's website at www.biotechltd.com.

[nicks46]

product said to ship next week from Pr today

[AAchem]

Nice gain on big volume today. Got in late today, hoping for a nice gain tomorrow.

[upyours]

IMHO, BIOHF has one of the best potentials of all stocks I have researched for quick profits and long term gains -
Based on only one million users = 12 million scripts a year at net profit of $5 to $6.00 each = Coma=pany has 78-Million shares out satanding, half of which are in the public's hands -
Each user needs to take this new class of drugs twice a day to control Diabetices Type 2 of which there are up to 350-Million in the world today and if only one million users buy 12 million scripts a year = $60-M in profits or close to $1.00 EPS. Production starts before years end. Approved in China, Mexico, Chile and Paru for starters - Product is patent protected in the US. NOW under 20 cents and news is due out this comming week - Long term Buy - Two competing drugs have serious side effects and this has none - It will soon be on the market at less than 50% of the cost of its competitors which are selling billions of dollars worth of their inferior products now. This shold be a blockbuster drug with a huge potential.